Prolinamide Derivatives for Selective NaV1.3 Sodium Channel Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by voltage-gated sodium channels lack subtype selectivity and optimal developability profiles, particularly for NaV1.3 channels, which are crucial for addressing various neurological and psychiatric disorders effectively.
Innovation Solution
The development of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide derivatives, including their pharmaceutically acceptable salts and solvates, which act as use-dependent sodium channel inhibitors, specifically targeting NaV1.3 channels with improved bioavailability and exposure profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If use-dependent sodium channel blockers are used to treat neurological and psychiatric disorders, then neuronal excitability is reduced and seizure propagation is prevented, but the drugs lack subtype selectivity and do not distinguish between different NaV channel subtypes
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (aromatic rings, heteroatoms at particular positions) that confer selectivity for NaV1.3 channels over other subtypes. The molecular structure is locally optimized with specific substituents at defined positions to interact with the unique binding site characteristics of NaV1.3, enabling subtype-specific inhibition while maintaining use-dependent blocking mechanism
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as the type of aromatic ring, position of heteroatoms, and substituent groups to optimize both selectivity for NaV1.3 and use-dependent blocking properties. By adjusting these chemical parameters, the compounds achieve enhanced affinity for the inactivated state of NaV1.3 channels while maintaining discrimination against other channel subtypes
2Reliability
If conventional sodium channel blockers are used, then broad-spectrum channel blocking is achieved, but the compounds lack optimal developability profiles including exposure and bioavailability
Solution Approach 1:
The patent applies parameter changes by optimizing physicochemical parameters of the compound molecules, including molecular weight, lipophilicity, and functional group composition, to improve oral bioavailability and exposure profiles. The structural modifications maintain channel blocking efficacy while enhancing pharmacokinetic properties suitable for clinical development
Solution Approach 2:
The patent employs composite materials by creating molecules that combine multiple functional elements: aromatic rings for membrane interaction, heteroatoms for hydrogen bonding, and specific substituents for channel binding. This composite structural approach achieves both effective channel blocking and improved pharmacokinetic properties for better developability
3Object-affected harmful factors
If non-selective sodium channel blockers are administered, then regional block of sensory neurons is achieved for pain relief, but the drugs may block resting or open states of channels at high concentrations reducing safety margin
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (aromatic rings, heteroatoms at particular positions) that confer selectivity for NaV1.3 channels over other subtypes. The molecular structure is locally optimized with specific substituents at defined positions to interact with the unique binding site characteristics of NaV1.3, enabling subtype-specific inhibition while maintaining use-dependent blocking mechanism
Solution Approach 2:
The patent employs partial or excessive action by achieving sufficient channel blocking at partial occupancy of the binding site. The compounds are designed to stabilize the inactivated state with high affinity, allowing effective pain relief at concentrations that do not excessively block resting or open states, thereby maintaining an adequate safety margin
Data Source
AI summary
The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.